Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.

FDA entrance sign 2016

A privately funded biosimilar pharmacovigilance effort may help industry push FDA to stop adding suffixes to non-proprietary names.

The studies are not being done specifically for that purpose, but the data may prove compelling should they show that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products